Quick Answer
IONIS PHARMACEUTICALS INC reported Revenue From Contract With Customer Excluding Assessed Tax of $943.71 million for the year ending 2025.
- IONIS PHARMACEUTICALS INC showed an increase of +33.8% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from IONIS PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $115.80 million | Q2 2017: $112.27 million | Q3 2017: $118.31 million | Q1 2018: $144.42 million | Q2 2018: $117.75 million | Q3 2018: $145.40 million | Q1 2019: $297.21 million | Q2 2019: $163.81 million | Q3 2019: $167.89 million | Q1 2020: $133.37 million | Q2 2020: $145.54 million | Q3 2020: $160.08 million | Q1 2021: $111.61 million | Q2 2021: $125.75 million | Q3 2021: $133.09 million | Q1 2022: $141.92 million | Q2 2022: $133.79 million | Q3 2022: $159.77 million | Q1 2023: $130.52 million | Q2 2023: $188.41 million | Q3 2023: $144.21 million | Q1 2024: $119.50 million | Q2 2024: $225.25 million | Q3 2024: $133.81 million | Q1 2025: $131.61 million | Q2 2025: $452.05 million | Q3 2025: $156.72 million.
- Over the full 11 years of available data (2015 to 2025), IONIS PHARMACEUTICALS INC's Revenue From Contract With Customer Excluding Assessed Tax has grown by 934.8%.
- Historical annual values: Fiscal year 2025: $943.71 million | Fiscal year 2024: $705.14 million | Fiscal year 2023: $787.65 million | Fiscal year 2022: $587.37 million | Fiscal year 2021: $810.46 million | Fiscal year 2020: $729.26 million | Fiscal year 2019: $1.12 billion | Fiscal year 2018: $599.67 million | Fiscal year 2017: $514.18 million | Fiscal year 2016: $372.78 million | Fiscal year 2015: $91.20 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: